Skip to Content Facebook Feature Image

Citi Enriches Private Market Offerings for Citigold Private Clients in Collaboration with Blackstone, Blue Owl and KKR

Asia Pacific

Citi Enriches Private Market Offerings for Citigold Private Clients in Collaboration with Blackstone, Blue Owl and KKR
Asia Pacific

Asia Pacific

Citi Enriches Private Market Offerings for Citigold Private Clients in Collaboration with Blackstone, Blue Owl and KKR

2026-01-29 11:45 Last Updated At:12:06

Citigold Private Clients will gain access to alternative asset classes including private equity and private infrastructure

HONG KONG SAR and SINGAPORE - Media OutReach Newswire - 29 January 2026 - Citi Hong Kong and Citi Singapore have announced strategic partnerships with leading global private market firms Blackstone, Blue Owl and KKR, to launch evergreen funds for high net-worth clients who are seeking enhanced wealth solutions and greater portfolio diversification.

Through the partnerships, Citigold Private Clients in Asia and the Middle East will gain access to private markets, including equity, credit, infrastructure, and real estate. These alternative asset classes have traditionally been reserved for institutional investors.

The funds will be structured in an evergreen format, offering simplified access to private markets with more flexible subscription and liquidity terms than traditional closed-ended private markets solutions, subject to a minimum initial holding period.

The launch of the funds has started and the funds will continue to be rolled out in the next few months.

Citigold Private Clients will be able to diversify their portfolios, capture opportunities for uncorrelated returns and long-term growth, as well as participate directly in the value creation inherent in private markets assets.

Ms Vicky Kong, Head of Wealth, Asia North and Australia, Citi, said: "In today's complex and volatile market, our clients are rightly seeking resilient, diversified sources of returns beyond traditional public markets. This collaboration with Blackstone, Blue Owl and KKR directly addresses that demand, providing sophisticated access to private markets that were once the exclusive domain of institutional and private bank investors. This is more than a product expansion, it's a significant step in our commitment to delivering comprehensive wealth management solutions to our affluent clients, and empowering our clients to build long-term portfolios fit for the future."

Ms Yeo Wenxian, Head of Wealth for Asia South, Citi, said: "We are excited to work with Blackstone, Blue Owl and KKR to leverage their industry leadership, investment expertise and robust deal-sourcing capabilities. These investment vehicles will deepen and broaden Citi's comprehensive wealth management offerings, further cementing our role as a trusted partner to our clients in their wealth journeys."

Mr Ed Huang, Head of Asia Pacific for Blackstone Private Wealth, said: "We are delighted to build on our longstanding relationship with Citi, combining its robust network and Blackstone's position as the world's largest alternatives manager, with proven performance in scaled offerings and a 23-year track record serving individual investors. We remain committed to expanding access to institutional-quality private market opportunities for Citi's high-net-worth clients, helping them diversify their portfolios. Education is the cornerstone of our platform, and we look forward to deepening our partnership by providing enhanced resources and insights into private markets."

Mr Sean Connor, CEO and Global Head of Private Wealth at Blue Owl Capital, said: "Our global partnership with Citi for their platform expansion in Asia is a critical milestone in our collective effort to provide best-in-class access to the private markets for investors. We are pleased to bring Blue Owl's differentiated investment capabilities, all-weather solutions, along with dedicated service and support for Citi financial advisors and their clients. Our priority is to continue to provide differentiated access to institutional-grade solutions that empower investors to unlock the full potential of the private markets in their portfolios with leading global partners like Citi."

Ms Jacqueline Zhuang, Managing Director and Head of Global Wealth Solutions Asia Pacific ex-Japan at KKR, said: "This strategic partnership with Citi provides their advisors and clients across Asia and the Middle East with differentiated access to KKR's suite of evergreen private equity, infrastructure and private credit strategies. Individual wealth investors expect access to the same private markets investment opportunities as institutions. Together with Citi, we are focused on delivering a comprehensive solution that combines investor service, education, and access to KKR's differentiated investment capabilities."

Hashtag: #Citibank

The issuer is solely responsible for the content of this announcement.

About Citi

Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 180 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.

Additional information may be found at | X: | LinkedIn: | YouTube: | Facebook:

HONG KONG SAR and SINGAPORE - Media OutReach Newswire - 29 January 2026 - Citi Hong Kong and Citi Singapore have announced strategic partnerships with leading global private market firms Blackstone, Blue Owl and KKR, to launch evergreen funds for high net-worth clients who are seeking enhanced wealth solutions and greater portfolio diversification.

Through the partnerships, Citigold Private Clients in Asia and the Middle East will gain access to private markets, including equity, credit, infrastructure, and real estate. These alternative asset classes have traditionally been reserved for institutional investors.

The funds will be structured in an evergreen format, offering simplified access to private markets with more flexible subscription and liquidity terms than traditional closed-ended private markets solutions, subject to a minimum initial holding period.

The launch of the funds has started and the funds will continue to be rolled out in the next few months.

Citigold Private Clients will be able to diversify their portfolios, capture opportunities for uncorrelated returns and long-term growth, as well as participate directly in the value creation inherent in private markets assets.

Ms Vicky Kong, Head of Wealth, Asia North and Australia, Citi, said: "In today's complex and volatile market, our clients are rightly seeking resilient, diversified sources of returns beyond traditional public markets. This collaboration with Blackstone, Blue Owl and KKR directly addresses that demand, providing sophisticated access to private markets that were once the exclusive domain of institutional and private bank investors. This is more than a product expansion, it's a significant step in our commitment to delivering comprehensive wealth management solutions to our affluent clients, and empowering our clients to build long-term portfolios fit for the future."

Ms Yeo Wenxian, Head of Wealth for Asia South, Citi, said: "We are excited to work with Blackstone, Blue Owl and KKR to leverage their industry leadership, investment expertise and robust deal-sourcing capabilities. These investment vehicles will deepen and broaden Citi's comprehensive wealth management offerings, further cementing our role as a trusted partner to our clients in their wealth journeys."

Mr Ed Huang, Head of Asia Pacific for Blackstone Private Wealth, said: "We are delighted to build on our longstanding relationship with Citi, combining its robust network and Blackstone's position as the world's largest alternatives manager, with proven performance in scaled offerings and a 23-year track record serving individual investors. We remain committed to expanding access to institutional-quality private market opportunities for Citi's high-net-worth clients, helping them diversify their portfolios. Education is the cornerstone of our platform, and we look forward to deepening our partnership by providing enhanced resources and insights into private markets."

Mr Sean Connor, CEO and Global Head of Private Wealth at Blue Owl Capital, said: "Our global partnership with Citi for their platform expansion in Asia is a critical milestone in our collective effort to provide best-in-class access to the private markets for investors. We are pleased to bring Blue Owl's differentiated investment capabilities, all-weather solutions, along with dedicated service and support for Citi financial advisors and their clients. Our priority is to continue to provide differentiated access to institutional-grade solutions that empower investors to unlock the full potential of the private markets in their portfolios with leading global partners like Citi."

Ms Jacqueline Zhuang, Managing Director and Head of Global Wealth Solutions Asia Pacific ex-Japan at KKR, said: "This strategic partnership with Citi provides their advisors and clients across Asia and the Middle East with differentiated access to KKR's suite of evergreen private equity, infrastructure and private credit strategies. Individual wealth investors expect access to the same private markets investment opportunities as institutions. Together with Citi, we are focused on delivering a comprehensive solution that combines investor service, education, and access to KKR's differentiated investment capabilities."

Hashtag: #Citibank

The issuer is solely responsible for the content of this announcement.

About Citi

Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 180 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.

Additional information may be found at | X: | LinkedIn: | YouTube: | Facebook:

** The press release content is from Media OutReach Newswire. Bastille Post is not involved in its creation. **

DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a Transthyretin Stabilizer for ATTR-CM in Australia, Singapore, South Korea, and Taiwan. The partnership combines BridgeBio’s biotech innovation and DKSH Healthcare’s integrated end-to-end commercialization platform to bring a new treatment option to patients.

SINGAPORE - EQS Newswire - 11 June 2026 - DKSH Business Unit Healthcare, a strategic healthcare business partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, has entered a distribution partnership with BridgeBio, a biotechnology company focused on genetic diseases. Under the terms of the agreement, DKSH will be responsible for the distribution and commercialization of the transthyretin stabilizer for ATTR-CM across Australia, Singapore, South Korea, and Taiwan.

Where approved, the product is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization1. ATTR-CM is a progressive, debilitating disease that diminishes quality of life, causes recurrent hospitalizations, and leads to premature death. This new treatment is not currently approved in the countries covered by this agreement and any commercialization will be subject to applicable regulatory approvals and local regulations.

DKSH will provide end-to-end solutions prioritizing healthcare access to patients, leveraging its expertise in regulatory affairs, medical affairs, market access, and launch excellence, as well as its robust distribution infrastructure and integrated commercial capabilities. DKSH is well positioned to support the introduction of this biotech innovation across the Territory following regulatory approvals.2 3 4

"Our strategic partnership with BridgeBio represents an important milestone as DKSH Healthcare enters a new chapter with a renewed vision for growth. United by a shared commitment to improve outcomes for underserved patients, we are proud to combine BridgeBio's scientific innovation with DKSH Healthcare's industry‑leading, end‑to‑end commercialization platform. Leveraging our deep market expertise, strong capabilities, and trusted execution across complex healthcare systems, we are well positioned to launch this biotech innovation and expand access to important new treatment options reliably, responsibly, and at scale, advancing on our mission to deliver Healthcare for All," said Patrik Grande, Global Head of Business Unit Healthcare, DKSH.

1 FDA, Full Prescribing Information. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216540s000lbl.pdf Last accessed March 2026.
2 Lane T, et al. Circulation. 2019;140(1):16-26.
3 Rintell D, et al. Orphanet J Rare Dis. 2021;16(1):70.
4 Nativi-Nicolau J, et al. ESC Heart Fail. 2021;8(5):3875-3884Hashtag: #DKSH

The issuer is solely responsible for the content of this announcement.

About DKSH

For more than 160 years, DKSH has been delivering growth for companies in Asia Pacific, Europe, and North America across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, e-commerce, distribution and logistics as well as after-sales services, following its purpose of enriching people's lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 35 markets with 26,840 specialists, generating net sales of CHF 11.1 billion in 2025. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, over-the-counter products and medical devices. With around 7,580 specialists, the Business Unit generated net sales of CHF 5.8 billion in 2025.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

Recommended Articles